Sandra Kweder

Sandra Kweder, M.D. is a Principal, Drug and Biological Products at ELIQUENT Life Sciences (formerly Greenleaf Health), bringing over 30 years of experience in U.S. and international medical products regulation and policy.13

Key points about Dr. Kweder's background:

FDA Career

• Served at the FDA for over 30 years in various leadership roles3
• Former Deputy Director of the FDA's Center for Drug Evaluation and Research (CDER) Office of New Drugs1
• Former Deputy Director of the FDA's Europe Office and Liaison to the European Medicines Agency (EMA)1
• Joined FDA in 1988 as a medical officer in the Division of Antiviral Drug Products1

Expertise

• Internal medicine expert3
• Extensive experience in drug development, regulatory affairs, and public health1
• Guided CDER's Office of New Drugs through significant growth and modernization from 2002 to 20161
• Led FDA's modernization of labeling and studying medicines in pregnancy and lactation1

Current Role

Dr. Kweder joined ELIQUENT Life Sciences (formerly Greenleaf Health) in early 2023 as Principal, Drug and Biological Products.5 In this role, she offers broad expertise in FDA regulatory processes, drug development strategies, and international regulatory collaboration.12

Education

Dr. Kweder received her education from Brown University.4

Her LinkedIn profile can be found under the username sandra-kweder-2b334912.45